Bisphosphonates and primary breast cancer risk: an updated systematic review and meta-analysis involving 963,995 women
Received 9 November 2018
Accepted for publication 20 May 2019
Published 18 July 2019 Volume 2019:11 Pages 593—603
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Ms Justinn Cochran
Peer reviewer comments 5
Editor who approved publication: Professor Henrik Toft Sørensen
Yupeng Liu,1,2 Xiaosan Zhang,3 Hongru Sun,2 Shu Zhao,4 Yuxue Zhang,5 Dapeng Li,2 Qingyuan Zhang,4 Yashuang Zhao2
1Department of Preventive Medicine, School of Public Health and Management, Wenzhou Medical University, Wenzhou 325035, People’s Republic of China; 2Department of Epidemiology, Public Health School of Harbin Medical University, Harbin 150081, People’s Republic of China; 3Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, People’s Republic of China; 4Department of Medical Oncology, The Third Affiliated Hospital of Harbin Medical University, Heilongjiang Cancer Hospital, Harbin 150081, People’s Republic of China; 5Department of Preventive Medicine, Public Health School of Harbin Medical University, Harbin 150081, People’s Republic of China
Importance: Prevention of primary breast cancer (BCa) in women is of great public health importance. The existing results from observational epidemiologic studies focused on the association between bisphosphonates and primary BCa risk have been inconsistent.
Objective: To update this systematic review and meta-analysis to assess the effect of bisphosphonates on primary BCa risk.
Data sources: We comprehensively searched MEDLINE, EMBASE, Cochrane libraries, ProQuest, and Web of Science through June 25, 2018 for relevant studies.
Study selection: Epidemiological studies that assessed the effect of bisphosphonates on the risk of primary BCa in women.
Data extraction and synthesis: We reported this meta-analysis according to the PRISMA guidelines. Available multivariable-adjusted effect estimates and corresponding 95% CIs were pooled with a random-effects model.
Main outcomes and measures: The prespecified main outcome was the risk of primary BCa.
Results: In total, five cohort studies involving 657,558 women and 12,991 primary BCa patients, three population-based case-control studies involving 54,701 primary BCa cases and 237,962 healthy controls and two randomized controlled trials (RCTs) involving 13,774 women and 165 primary BCa patients were included in this meta-analysis. Bisphosphonates were associated with a 12% decreased risk of primary BCa (RR, 0.88; 95% CI, 0.83–0.94). However, when we analyzed study designs separately, the pooled results from observational studies were inconsistent with that from RCTs. The observed association of primary BCa risk with long-term use (≥1 year) of bisphosphonates seemed to be more robust and stronger than that of short-term use (<1 year) (RR, 0.75; 95% CI, 0.66–0.84; and 0.90; 95% CI, 0.84–0.97; respectively).
Conclusion: This meta-analysis adds to the body of evidence for an association between bisphosphonates and a significantly decreased risk of primary BCa. However, future large-scale RCTs are required to validate this concern.
Keywords: bisphosphonates, primary breast cancer risk, meta-analysis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]